Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open

BACKGROUND: Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. We report health-related quality of life (HRQoL) outcomes in patients with ulcerative colitis in the phase 3 open-label, long-term extension study, OCTAVE Open. METHODS: The Inflammatory...

Descripción completa

Detalles Bibliográficos
Autores principales: Biedermann, Luc, Dubinsky, Marla C, Vermeire, Séverine, Fellmann, Marc, Gardiner, Sean, Hur, Peter, Mundayat, Rajiv, Panés, Julian, Rubin, David T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472737/
https://www.ncbi.nlm.nih.gov/pubmed/36242764
http://dx.doi.org/10.1093/ibd/izac222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472737/
https://www.ncbi.nlm.nih.gov/pubmed/36242764
http://dx.doi.org/10.1093/ibd/izac222

Ejemplares similares